Adjuvant GEMOX Did Not Improve RFS for Localized Biliary Tract Cancer

Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial.

Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news